Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Nov;44(11):2006-2008.
doi: 10.1007/s00134-018-5374-7. Epub 2018 Sep 25.

Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial

Jennifer M Kaplan  1 , Basilia Zingarelli  2 , Kelli Krallman  2 , Sonya Tang Girdwood  2 , Denise Lagory  3 , Tomoyuki Mizuno  4 , Lin Fei  5 , Hector R Wong  2 , Alexander A Vinks  4
Affiliations
Clinical Trial

Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial

Jennifer M Kaplan et al. Intensive Care Med. 2018 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Source of Funding: BZ, KK, STG, DL, TM, LF, AV reports no conflicts of interest.

Figures

Fig. 1
Fig. 1
(A) Treatment group and route for pioglitazone administration by subject. (B) Pharmacokinetic profile for subjects randomized to the pioglitazone group. Pioglitazone concentration of individual subjects over time. Black symbols = subjects who received drug by mouth (PO route). White symbols = subjects who received drug by NG route. (C) Pioglitazone area under the curve (AUC) estimates for subjects by route of administration. Black symbols = PO route, White symbols = NG route. (D) Pioglitazone concentration as the total AUC/number of days receiving the drug in subjects who took the drug PO versus by NG tube.
See this image and copyright information in PMC

References

    1. Schlapbach LJ, MacLaren G, Festa M, Alexander J, Erickson S, Beca J, Slater A, Schibler A, Pilcher D, Millar J, Straney L, Australian, New Zealand Intensive Care Society Centre for O, Resource E, Australian, New Zealand Intensive Care Society Paediatric Study G, (2017) Prediction of pediatric sepsis mortality within 1 h of intensive care admission. Intensive Care Med 43: 1085–1096. - PubMed
    1. Thompson K, Taylor C, Jan S, Li Q, Hammond N, Myburgh J, Saxena M, Venkatesh B, Finfer S, (2018) Health-related outcomes of critically ill patients with and without sepsis. Intensive Care Med 44: 1249–1257. - PubMed
    1. Kaplan JM, Cook JA, Hake PW, O’Connor M, Burroughs TJ, Zingarelli B, (2005) 15-Deoxy-delta(12,14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock 24: 59–65. - PubMed
    1. Kaplan JM, Denenberg A, Monaco M, Nowell M, Wong H, Zingarelli B, (2010) Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Med 36: 123–130. - PMC - PubMed
    1. Christensen ML, Meibohm B, Capparelli EV, Velasquez-Mieyer P, Burghen GA, Tamborlane WV, (2005) Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol 45: 1137–1144. - PubMed

Associated data